Advertisement

Comment on: Malignant potential and specific characteristics of pure main duct type intraductal papillary mucinous neoplasm

Published:August 13, 2022DOI:https://doi.org/10.1016/j.ejso.2022.08.009
      Currently, it remains an unmet need to accurately differentiate pancreatic mucinous cysts (intraductal papillary mucinous neoplasm, IPMN) and mucinous cystic neoplasm with underlying risk of progressing to malignancy [
      • Hayashi H.
      • Baba H.
      Precision surgery with the genetic assessment for operable pancreatic cancer beyond the radiological assessment alone.
      ,
      • Capurso G.
      • Paiella S.
      • Falconi M.
      Screening for pancreatic cancer-a compelling challenge.
      ]. Recently, in the report published by Y. Fujita et al., entitled Malignant potential and specific characteristics of pure main duct type intraductal papillary mucinous neoplasm [
      • Fujita Y.
      • Hirono S.
      • Kawai M.
      • Okada K.
      • Miyazawa M.
      • Kitahata Y.
      • et al.
      Malignant potential and specific characteristics of pure main duct type intraductal papillary mucinous neoplasm.
      ], the authors retrospectively analyzed clinicopathological characteristics incorporated serum and pancreatic juice protein measurements, clinical and radiographic data from 1100 patients with IPMN (387 patients underwent surgery, 79 with main duct (MD) type, 146 with branch duct (BD) type and 162 with Mixed-type). This study found that mural nodule height (≥5mm) and preoperative pancreatic juice CEA level (≥50ng/ml) were two independent predictors for high-grade dysplasia (HGD) and invasive intraductal papillary mucinous carcinoma (IPMC).
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to European Journal of Surgical Oncology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Hayashi H.
        • Baba H.
        Precision surgery with the genetic assessment for operable pancreatic cancer beyond the radiological assessment alone.
        Hepatobiliary Surg Nutr. 2021; 10: 261-263https://doi.org/10.21037/hbsn-20-820
        • Capurso G.
        • Paiella S.
        • Falconi M.
        Screening for pancreatic cancer-a compelling challenge.
        Hepatobiliary Surg Nutr. 2021; 10: 264-266https://doi.org/10.21037/hbsn-20-861
        • Fujita Y.
        • Hirono S.
        • Kawai M.
        • Okada K.
        • Miyazawa M.
        • Kitahata Y.
        • et al.
        Malignant potential and specific characteristics of pure main duct type intraductal papillary mucinous neoplasm.
        Eur J Surg Oncol. 2022; 48: 1054-1061https://doi.org/10.1016/j.ejso.2021.11.137
        • Tjaden C.
        • Sandini M.
        • Mihaljevic A.L.
        • Kaser J.
        • Khristenko E.
        • Mayer P.
        • et al.
        Risk of the watch-and-wait concept in surgical treatment of intraductal papillary mucinous neoplasm.
        JAMA Surg. 2021; 156: 818-825https://doi.org/10.1001/jamasurg.2021.0950

      Linked Article